Etoraidate was injected i.v. within 10 or 60s at various doses. After etonudate 0.3 nig kg the plasma concentration was 1.6 fig ml at 1 min after the end of injection. For about 7min a good hypnotic effect (stages CQ-DJ was observed on the e.e.g. recording. For surgical procedures, however, a combination with analgesic drugs appeared to be necessary. When the dose of etomidate was increased (0.1 -0.4 mg kg ) a linear increase in plasma concentration and slow e.e.g activity was observed concomitantly. Anaesthesia could be prolonged with additional injections or with continuous infusion. Each additional injection produced a steep increase in concentration of short duration with marked deepening of hypnosis. The infusion induced only a moderate increase in plasma concentration, whereas the depth of sleep during the period of infusion remained nearly the same. E.e.g. changes induced by etomidate are similar to those after barbiturates and other i.v. anaesthetics
Following the initial animal experiments carried out at Janssen Pharmaceutica (Janssen et al., 1971) , etomidate was first used by two of the authors in 1972 in man under e.e.g. and e.e.g. control. After further experimental studies and 8 years of clinical research, this substance became a successful shortacting hypnotic with minimal effects on the circulation (Bruckner et al., 1974; Doenicke et al., 1974; Kettler et al., 1974) . The possibility of histamine release can almost be excluded (Doenicke, Lorenz et al., 1973) .
That hypnosis could be prolonged by additional injections of etomidate has been known for'some time and has been confirmed by e.e.g. recordings (Doenicke, Kugler et al., 1973) . However, for such clinical applications there was a lack of information on the plasma concentration.
At the end of 1974 Wynants, Woestenborghs and Heykants published a method enabling investigators to determine etomidate in the plasma by gas chromatography, using the unlabelled drug. By means of this procedure, we have established the plasma concentration occurring after different etomidate regimens and compared these results with the e.e.g. findings (Doenicke et al., 1975) . 
SUBJECTS AND MATERIALS
Fifteen healthy male volunteers, aged 20-3Oyr, took part in this study, giving informed consent.
Group 1
Six subjects received etomidate 0.3 rag kg" 1 at 2-week intervals, on the first occasion over 10 s and on the second occasion over 60 s.
Group 2
Six subjects each received etomidate 0.3mgkg"' over 60 s followed by 0.15 mg kg" 1 over 60 s at 5 min and at 12 min. Two weeks later they received the same initial dose (0.3mgkg~') followed by 0.3mgkg~' in 250 ml of glucose as a continuous infusion injected between the 5th and 14th min.
Group 3
Three subjects each received, at 10-day intervals, a total of four anaesthetics. Etomidate was injected in increasing doses, 0.1, 0.2, 0.3 and 0.4mgkg"', always within 10 s.
Premedication was the same for all groups: atropine 0.5 mg 15 min before the start of anaesthesia, diazepam 0.05 mg kg" 1 10 min before, and fentanyl 0.1 mg i.v. 5 min before. Diazepam and fentanyl were given to avoid the occurrence of myoclonic movements.
Blood 8 ml was sampled from an arm vein at the 2, 4, 7, 9, 14, 16, 20, 28, 44 , and 60 min after the end of injection. The blood was stored in cooled test tubes containing sodium citrate and potassium fluoride. Blood samples were centrifuged at 3000 rev min" 1 and plasma was separated from the blood.
For gas chromatographic determination propoxate 1 ng (propyl-phenyl-ethyl-lH imidazol-5-carboxylate) was added to the plasma and used as internal standard. This standard was used throughout the chemical extraction of the substance.
The gas chromatograph was a Varian 2140 with an alkali flame ionization detector. After the injection of the sample to the gas chromatograph the peak of etomidate appeared first, followed by that of propoxate. The amount of etomidate in the sample was measured by a comparison of these two peaks.
Concentrations of etomidate between 0.01 ngmT 1 and 10/xgml" 1 could be measured. The error was 5% for the greater concentration (lO^gml"') and 20% for the lesser concentration (0.01 ngml" 1 ) (Wynants, Woestenborghs and Heykants, 1974) .
From the time of premedication, the e.c.g. and arterial pressure (Riva-Rocci) were monitored continuously. The e.e.g. was recorded on a 12-channel Hellige-apparatus (Kugler, Doenicke and Laub, 1977) .
The e.e.g. curves were evaluated visually and classified according to the e.e.g. stages in each successive 40-s epoch (table I) and then illustrated in a compressed time-scale giving a display of the spectrum of vigilance and sleep (vigilosomnogram).
The following time points of the spectrum were compared with the corresponding plasma concentrations: (a) period of latency: the period between the start of the injection and the first e.e.g. changes. RESULTS The e.e.g. stages after the administration of etomidate were comparable to the e.e.g. patterns after barbiturates and other i.v. anaesthetics. After a period of latency lasting 10-30 s (depending on the speed of injection), a short initial activation phase of a few seconds occurred with 6-10 s e.e.g. activity ( fig. I )-Subsequently, this e.e.g. changed very rapidly to high, slower activity with superimposed lower, rapid waves. When hypnotic activity subsided, mixed activity decreased and more prolonged, slow waves were observed over the posterior region of the brain. Paroxysmal, or burst suppression, activities did not occur. (fig. 2 ) Group 1. Within the first minute after the end of injection, peak plasma concentrations of 1.59 (0.48-2.67) ^gmT' were reached after rapid injection; 1.30±0.38ngmn' after slow injection. All the data presented here were expressed as mean values ± SD. At 1 min plasma concentration was approximately 0.6 fig ml" 1 , and at 32 min the concentration was approximately 0.075 /ig ml" 1 with both types of injection.
Rapid and slow injection
The end of peak activity occurred after 427 ± 85 s for the rapid injection and after 440 ± 112 s for the slow injection, both read from the e.e.g. (fig. 2) . The difference was not statistically significant. The total duration of sleep did not differ substantially either: 770 ±218 s after the rapid injection v. 700 ± 185 s after the slow injection. The plasma-time diagrams revealed an etomidate concentration of 0.14 tig ml" • at the end of peak activity and of 0.11 ngml" 1 at the end of activity.
Prolongation of anaesthesia by additional injections or continuousinfusion(tig. 3)
Group 2. Up to the 4th min the same pronounced initial decrease in concentration observed in the first group was noticed. Thereafter, each additional injection, as expected, produced a pronounced, rapid increase in plasma concentration; the subsequent decrease in concentration resembled that of the first injection.
Each additional injection had an effect on the depth of sleep as noted in the e.e.g. (fig. 3 , upper part). After 22 min individual values showed considerable variation with a tendency to deep, posthypnotic stages.
No such changes in plasma concentration were noted when etomidate was administered by continuous infusion (fig. 4) . From 0.34 ± 0.06 ng ml" 1 at the beginning of the infusion, the plasma concentration increased to 0.54±0.12figmr' at the end of the infusion; at 20 min no difference was apparent between bolus injection and infusion. The peak of activity after both regimens lasted about 22 min, whereas the end of activity appeared at about 34 min.
Increasing dose of etomidate
Group 3. The vigilosomnogram ( fig. 5A) showed that increasing doses of etomidate produce a deeper and longer hypnotic effect. There was a good relationship between plasma concentration and the observed changes in vigilosomnogram ( fig. 5B ). The plasma concentration of etomidate at the end of peak activity was 0.12 ±0.04figmT' at a dose of O.lmgkg" 1 and 0.22±0.05ngml" 1 at 0.4mgkg-' (P<0.05). By increasing the doses of etomidate "acute tolerance" was observed ( fig. 6 ) as it has been described for barbiturates (Brodie et al., 1951; Dundee, Price and Dripps, 1956; Maynert and Klingmann, 1960 ). 
Kinetics of etomidate
The clear biphasic decrease in the plasma concentration curve after a single bolus injection can be explained by means of a two-compartment open model.
After a rapid injection, etomidate immediately entered the central or distribution compartment, represented by the intravascular volume, which is the sole compartment involved in excretion. There is a rapid exchange between this compartment and the effector compartment c.s.f. and specific receptors, where the drug exhibits its activity (Dost, 1968) . Both distribution spaces can be regarded as a common reference compartment with a volume of 7.5 litre.
In addition to the plasma, this compartment also comprises well-perfused organs. The half-life of etomidate of 1 min for this compartment correlates well with the short hypnotic activity of the drug.
After 8 min the concentration decreased less rapidly than before, maintaining an equilibrium between plasma and tissue concentrations (zero exchange of drug). The changes in this phase correspond with the elimination of drug.
The distribution volume for etomidate was 145 litre, the elimination constant 0.03 min and the elimination half-life 29 min. DISCUSSION At pH 7.4 etomidate was 65% bound to albumin, the total binding to human plasma being substantially greater (90%). Etomidate is thus one of the substances with very high protein binding (Mannes and Doenicke, 1977) . This might explain why the differences between the effects of rapid and slow injections are so small with regard to plasma concentration and hypnotic activity. A conspicuous feature in this respect is the fluctuation of measured values during the 1 st min following a single rapid injection. In some subjects, the processes of distribution probably occur at such a rapid rate that at the time of measuring a large proportion of the drug has already been carried to well perfused organs.
In recent studies, the detection limit for unlabelled etomidate could be lowered still further by perfecting the method devised by Wynants (van Hamme, Ghoneim and Ambre, 1978; Schuttler, Wilms et ah, 1980) . Thus, Schuttler, Wilms and others (1980) succeeded in following the pathways of etomidate up to 4 h after a bolus injection; van Hamme, Ghoneim and Ambre (1978) 7"| = 29min, V=158 litre (second compartment); our studies: T{ = 29min, V= 145 litre). Both investigators, however, recorded their measurements in patients who underwent ophthalmic surgery lasting up to 3-5 h. Thus, the presence of other anaesthetic drugs might influence the plasma concentration of etomidate through biological changes.
Measurements by van Hamme started only after 4 min, and by Schiittler after 2 min, so that initial concentration peaks were not recorded and the plasma curve was too flat (van Hamme, Ghoneim and Ambre, 1978) . This might explain why a threecompartment open model, used in their studies, showed the volume and etomidate half-life value for the central compartment to be great. Van Hamme (continuous measurements of the plasma concentration for lOh) calculated by a three-compartment model a distribution volume of 335 litre and a half life of 4.6±2.6h. These data suggest that the last time-point in our measurements might not resemble an equilibrium state of the substance between plasma and tissue.
Because of the short half-life of etomidate, additional injections to prolong hypnosis have to be administered repeatedly. These are accompanied by high plasma concentrations which are reflected in pronounced e.e.g. depression.
In all volunteers, the depth of sleep decreased between 11 and 14 min, in two of them to the point at which the level was less than stage Q. This suggests that the second additional injection should be given in the 10th min. increased from 0.34^gml~' to and remained at that value until the end of the infusion. If the concentration becomes less than 0.19ngml~' lighter sleep stages occur with wakening at values less than 0.12 ng ml" 1 ( fig. 4) . Schiittler, Stoeckel and others (1980) reported an infusion regimen with two different doses. Etomidate 80 mg was infused within 10 min to induce sleep. Subsequently, a plasma concentration of 0.5/igmT 1 was maintained with etomidate 0.8 mg min" 1 . Plasma concentration on recovery from sleep was approximately 0.3 pg ml"', 2.5 times greater than in our studies. The apparent reason for these discrepancies must be the absence of premedication in Schuttler's study. As a consequence, they noticed myoclonia in each volunteer at induction and recovery. It is worthwhile mentioning that the use of an analgesic (fentanyl, nitrous oxide) in clinical practice is very important when etomidate is used as an hypnotic drug.
The bolus injection of etomidate seems to us a safer form of induction than is the infusion, especially since etomidate 80 mg within 10 min represents a very high dose. Subsequently, the continuous infusion is set according to the patient's requirements, the premedication used and the type of surgery.
The dose we chose is certainly too great for prolonged anaesthesia. After 20 min a dose of 0.5-0.8 mg min" 1 appeared to suffice. In a late study Schwilden and co-workers (1981) have shown that, after 30 min, this dose can be further decreased.
